MedDataX Logo

Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition

NCT ID: NCT02598167

Last Updated: 2017-10-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

223 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-12-07

Study Completion Date

2016-02-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multi-center non-interventional, observational, cross-sectional study in adult participants with relapsing remitting multiple sclerosis (RRMS) will evaluate the participants' preferences for disease modifying treatments (DMT) in routine clinical practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis, Relapsing-Remitting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RRMS Population

Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at least 3 months according to standard local clinical practice will be included.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants aged greater than or equal to (\>/=) 18 years
* Participants who have a diagnosis of RRMS as documented in their medical records
* Participants who have been prescribed a DMT for at least 3 months
* Participants who have an expanded disability status scale (EDSS) score of 1-6 points

Exclusion Criteria

\- Participants with any personal or medical condition that in opinion of the investigator would interfere with or make impossible proper participation in the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Sant Joan Despi Moises Broggi; Servicio de Neurología

Sant Joan Despí, Barcelona, Spain

Site Status

Hospital Universitario Marques de Valdecilla; Servicio de Neurología

Santander, Cantabria, Spain

Site Status

Hospital General de Castellon; Servicio de Neurología

Castellon, Castellon, Spain

Site Status

Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Neurología

Lleida, Lerida, Spain

Site Status

Hospital Universitario del Sureste; Servicio de Neurologia

Arganda, Madrid, Spain

Site Status

Hospital Universitario Rey Juan Carlos de Móstoles; Servicio de Neurología

Móstoles, Madrid, Spain

Site Status

Hospital Quiron de Madrid; Servicio de Neurologia

Pozuelo de Alarcón, Madrid, Spain

Site Status

Complejo Hospitalario Universitario de Vigo - Xeral Cies; Servicio de Neurologia

Vigo, Pontevedra, Spain

Site Status

Hospital Universitario de Canarias; Servicio de Neurologia

San Cristóbal de La Laguna, Tenerife, Spain

Site Status

Hospital del Mar; Servicio de Neurologia

Barcelona, , Spain

Site Status

Hospital Universitario Reina Sofia; Servicio de Neurologia

Córdoba, , Spain

Site Status

Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Neurologia

Girona, , Spain

Site Status

Hospital General Universitario Gregorio Marañon; Servicio de Neurologia

Madrid, , Spain

Site Status

Fundacion Jimenez Diaz; Servicio de Neurología

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre; Servicio de Neurologia

Madrid, , Spain

Site Status

Hospital Clinico Universitario de Valencia; Servicio de Neurologia

Valencia, , Spain

Site Status

Hospital Universitario Dr. Peset; Servicio de Neurologia

Valencia, , Spain

Site Status

Hospital Universitario La Fe; Unidad de Esclerosis Multiple

Valencia, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ML29715

Identifier Type: -

Identifier Source: org_study_id